Disease Information
General Information of the Disease (ID: DIS00022)
Name |
Tissue pyogenic bacterial infection
|
---|---|
ICD |
ICD-11: 1B7Y
|
Resistance Map |
Type(s) of Resistant Mechanism of This Disease
IDUE: Irregularity in Drug Uptake and Drug Efflux
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Drug
Approved Drug(s)
11 drug(s) in total
Ampicillin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [1] | |||
Resistant Disease | Staphylococcus infection [ICD-11: 1B7Y.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Ampicillin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Pseudomonas aeruginosa isolates | 287 | ||
Staphylococcus aureus isolates | 1280 | |||
Klebsiella pneumoniae isolates | 573 | |||
Acinetobacter isolates | 469 | |||
Enterobacter cloacae isolates | 550 | |||
Experiment for Drug Resistance |
Disk diffusion method assay | |||
Mechanism Description | Up-regulation of P-glycoprotein led to ampicillin resistance in the staphylococcus infection. |
Cefazolin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [1] | |||
Resistant Disease | Staphylococcus infection [ICD-11: 1B7Y.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cefazolin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Pseudomonas aeruginosa isolates | 287 | ||
Staphylococcus aureus isolates | 1280 | |||
Klebsiella pneumoniae isolates | 573 | |||
Acinetobacter isolates | 469 | |||
Enterobacter cloacae isolates | 550 | |||
Experiment for Drug Resistance |
Disk diffusion method assay | |||
Mechanism Description | Up-regulation of P-glycoprotein led to cefazolin resistance in the staphylococcus infection. |
Cefotetan
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [1] | |||
Resistant Disease | Staphylococcus infection [ICD-11: 1B7Y.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cefotetan | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Pseudomonas aeruginosa isolates | 287 | ||
Staphylococcus aureus isolates | 1280 | |||
Klebsiella pneumoniae isolates | 573 | |||
Acinetobacter isolates | 469 | |||
Enterobacter cloacae isolates | 550 | |||
Experiment for Drug Resistance |
Disk diffusion method assay | |||
Mechanism Description | Up-regulation of P-glycoprotein led to ampicillin resistance in the staphylococcus infection. |
Ciprofloxacin XR
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [1] | |||
Resistant Disease | Staphylococcus infection [ICD-11: 1B7Y.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Ciprofloxacin XR | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Pseudomonas aeruginosa isolates | 287 | ||
Staphylococcus aureus isolates | 1280 | |||
Klebsiella pneumoniae isolates | 573 | |||
Acinetobacter isolates | 469 | |||
Enterobacter cloacae isolates | 550 | |||
Experiment for Drug Resistance |
Disk diffusion method assay | |||
Mechanism Description | Up-regulation of P-glycoprotein led to ciprofloxacin resistance in the staphylococcus infection. |
Clindamycin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: ABC protein lsaC (lsaC-Unclear) | [2] | |||
Resistant Disease | Streptococcus agalactiae infection [ICD-11: 1B21.2] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Clindamycin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli TOP10 | 83333 | ||
Staphylococcus aureus ATCC 29213 | 1280 | |||
Streptococcus agalactiae UCN70 | 1311 | |||
Streptococcus agalactiae isolates | 1311 | |||
Streptococcus agalactiae BM132 | 1319 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay; Allelic frequency measurement assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Expression of this novel gene, named lsa(C), in S. agalactiae BM132 after cloning led to an increase in MICs of lincomycin (0.06 to 4 ug/ml), clindamycin (0.03 to 2 ug/ml), dalfopristin (2 to >32 ug/ml), and tiamulin (0.12 to 32 ug/ml), whereas no change in MICs of erythromycin (0.06 ug/ml), azithromycin (0.03 ug/ml), spiramycin (0.25 ug/ml), telithromycin (0.03 ug/ml), and quinupristin (8 ug/ml) was observed. The phenotype was renamed the LS(A)P phenotype on the basis of cross-resistance to lincosamides, streptogramins A, and pleuromutilins. |
Dalfopristin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: ABC protein lsaC (lsaC-Unclear) | [2] | |||
Resistant Disease | Streptococcus agalactiae infection [ICD-11: 1B21.2] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Dalfopristin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli TOP10 | 83333 | ||
Staphylococcus aureus ATCC 29213 | 1280 | |||
Streptococcus agalactiae UCN70 | 1311 | |||
Streptococcus agalactiae isolates | 1311 | |||
Streptococcus agalactiae BM132 | 1319 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay; Allelic frequency measurement assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Expression of this novel gene, named lsa(C), in S. agalactiae BM132 after cloning led to an increase in MICs of lincomycin (0.06 to 4 ug/ml), clindamycin (0.03 to 2 ug/ml), dalfopristin (2 to >32 ug/ml), and tiamulin (0.12 to 32 ug/ml), whereas no change in MICs of erythromycin (0.06 ug/ml), azithromycin (0.03 ug/ml), spiramycin (0.25 ug/ml), telithromycin (0.03 ug/ml), and quinupristin (8 ug/ml) was observed. The phenotype was renamed the LS(A)P phenotype on the basis of cross-resistance to lincosamides, streptogramins A, and pleuromutilins. |
Daptomycin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Cardiolipin synthase 2 (CLS2) | [3] | |||
Resistant Disease | Complicated soft tissue infection [ICD-11: 1B7Y.0] | |||
Molecule Alteration | Missense mutation | p.A23V+p.T33N+p.L52F+p.F60S |
||
Resistant Drug | Daptomycin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Staphylococcus aureus isolates | 1280 | ||
Staphylococcus aureus MRSA32 [A5948] | 553567 | |||
Staphylococcus aureus RN6607 [A8115] | 553573 | |||
Staphylococcus aureus RN9120 [A8117] | 553574 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay; Allelic frequency measurement assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Mutation in each of these genes act similarly to reduce the net-negative charge of the cell membrane leading to electrorepulsion of daptomycin. They may act in isolation or in concert with each other, particularly for mutations in mprF and cls2. | |||
Key Molecule: Phosphatidylglycerophosphate synthase (PGSA) | [3] | |||
Resistant Disease | Complicated soft tissue infection [ICD-11: 1B7Y.0] | |||
Molecule Alteration | Missense mutation | p.V59D+p.A64V+p.K75N+p.Ins.G76;Q77+p.S177F |
||
Resistant Drug | Daptomycin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Staphylococcus aureus isolates | 1280 | ||
Staphylococcus aureus MRSA32 [A5948] | 553567 | |||
Staphylococcus aureus RN6607 [A8115] | 553573 | |||
Staphylococcus aureus RN9120 [A8117] | 553574 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay; Allelic frequency measurement assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Mutation in each of these genes act similarly to reduce the net-negative charge of the cell membrane leading to electrorepulsion of daptomycin. They may act in isolation or in concert with each other, particularly for mutations in mprF and cls2. |
Levofloxacin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [1] | |||
Resistant Disease | Staphylococcus infection [ICD-11: 1B7Y.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Levofloxacin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Pseudomonas aeruginosa isolates | 287 | ||
Staphylococcus aureus isolates | 1280 | |||
Klebsiella pneumoniae isolates | 573 | |||
Acinetobacter isolates | 469 | |||
Enterobacter cloacae isolates | 550 | |||
Experiment for Drug Resistance |
Disk diffusion method assay | |||
Mechanism Description | Up-regulation of P-glycoprotein led to levofloxacin resistance in the staphylococcus infection. |
Lincomycin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: ABC protein lsaC (lsaC-Unclear) | [2] | |||
Resistant Disease | Streptococcus agalactiae infection [ICD-11: 1B21.2] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Lincomycin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli TOP10 | 83333 | ||
Staphylococcus aureus ATCC 29213 | 1280 | |||
Streptococcus agalactiae UCN70 | 1311 | |||
Streptococcus agalactiae isolates | 1311 | |||
Streptococcus agalactiae BM132 | 1319 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay; Allelic frequency measurement assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Expression of this novel gene, named lsa(C), in S. agalactiae BM132 after cloning led to an increase in MICs of lincomycin (0.06 to 4 ug/ml), clindamycin (0.03 to 2 ug/ml), dalfopristin (2 to >32 ug/ml), and tiamulin (0.12 to 32 ug/ml), whereas no change in MICs of erythromycin (0.06 ug/ml), azithromycin (0.03 ug/ml), spiramycin (0.25 ug/ml), telithromycin (0.03 ug/ml), and quinupristin (8 ug/ml) was observed. The phenotype was renamed the LS(A)P phenotype on the basis of cross-resistance to lincosamides, streptogramins A, and pleuromutilins. |
Nitrofurantoin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [1] | |||
Resistant Disease | Staphylococcus infection [ICD-11: 1B7Y.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Nitrofurantoin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Pseudomonas aeruginosa isolates | 287 | ||
Staphylococcus aureus isolates | 1280 | |||
Klebsiella pneumoniae isolates | 573 | |||
Acinetobacter isolates | 469 | |||
Enterobacter cloacae isolates | 550 | |||
Experiment for Drug Resistance |
Disk diffusion method assay | |||
Mechanism Description | Up-regulation of P-glycoprotein led to nitrofurantoin resistance in the staphylococcus infection. |
Tiamulin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: ABC protein lsaC (lsaC-Unclear) | [2] | |||
Resistant Disease | Streptococcus agalactiae infection [ICD-11: 1B21.2] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Tiamulin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli TOP10 | 83333 | ||
Staphylococcus aureus ATCC 29213 | 1280 | |||
Streptococcus agalactiae UCN70 | 1311 | |||
Streptococcus agalactiae isolates | 1311 | |||
Streptococcus agalactiae BM132 | 1319 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay; Allelic frequency measurement assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Expression of this novel gene, named lsa(C), in S. agalactiae BM132 after cloning led to an increase in MICs of lincomycin (0.06 to 4 ug/ml), clindamycin (0.03 to 2 ug/ml), dalfopristin (2 to >32 ug/ml), and tiamulin (0.12 to 32 ug/ml), whereas no change in MICs of erythromycin (0.06 ug/ml), azithromycin (0.03 ug/ml), spiramycin (0.25 ug/ml), telithromycin (0.03 ug/ml), and quinupristin (8 ug/ml) was observed. The phenotype was renamed the LS(A)P phenotype on the basis of cross-resistance to lincosamides, streptogramins A, and pleuromutilins. |
Investigative Drug(s)
1 drug(s) in total
Ampicillin-sulbactam
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [1] | |||
Resistant Disease | Staphylococcus infection [ICD-11: 1B7Y.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Ampicillin-sulbactam | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Pseudomonas aeruginosa isolates | 287 | ||
Staphylococcus aureus isolates | 1280 | |||
Klebsiella pneumoniae isolates | 573 | |||
Acinetobacter isolates | 469 | |||
Enterobacter cloacae isolates | 550 | |||
Experiment for Drug Resistance |
Disk diffusion method assay | |||
Mechanism Description | Up-regulation of P-glycoprotein led to ampicillin-sulbactam resistance in the staphylococcus infection. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.